Preview

Рецепт

Расширенный поиск

Острые вопросы фармакотерапии коронавирусной инфекции.Позиция клинических фармакологов

https://doi.org/10.34883/PI.2020.23.5.003

Полный текст:

Аннотация

COVID-19 (от англ. COronaVIrus Disease 2019) – новая коронавирусная болезнь 2019 года – заболевание, вызванное новым коронавирусом SARS-CoV-2, впервые выявленное в городе Ухань, провинция Хубэй, Китай. Вирусопосредованное повреждение многих органов, главным образом дыхательных путей, активация иммунного ответа с высвобождением провоспалительных цитокинов, а также гиперактивация каскада свертывания и агрегации тромбоцитов, приводящая к микро- и макрососудистому тромбозу, являются основными патологическими признаками COVID-19.В статье представлены клинико-фармакологические особенности основных лекарственных средств, применяемых для лечения пациентов с коронавирусной инфекцией, критическая оценка современных данных об «этиотропных» препаратах, противовоспалительных средствах, антитромботических препаратах. Особое внимание уделено оценке эффективности и безопасности их применения, предупреждению нежелательных эффектов.

Об авторах

Л. Н. Гавриленко
Белорусский государственный медицинский университет
Беларусь


И. Н. Кожанова
Белорусский государственный медицинский университет
Беларусь


И. С. Романова
Белорусский государственный медицинский университет
Беларусь


О. Г. Садовская
6-я городская клиническая больница города Минска
Беларусь


Список литературы

1. The New York Times. Coronavirus Live Updates: W.H.O. Declares Pandemic as Number of Infected Countries Grows. The New York Times. Available at https://www.nytimes.com/2020/03/11/world/coronavirus-news.html#link-682e5b06. 2020 Mar 11 (accessed 24 march 2020).

2. CDC. 2019 Novel Coronavirus, Wuhan, China: Prevention & Treatment. CDC. Available at: https://www.cdc.gov/coronavirus/2019-ncov/about/ prevention-treatment.html. January 26, 2020 (accessed 27 January 2020).

3. Bagnenko S., Rassohin V., Belyakov N. (2020) Koronavirusnaya infekciya COVID-19. Lechenie i profilaktika [Coronavirus infection COVID-19. Treatment and prevention]. апрель2020 Available at: https://www.1spbgmu.ru/images/home/covid19_16.04.2020.pdf (accessed 27 April 2020).

4. Wang Y, Zhang D, Du G et al. (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicenter trial. Available at: https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31022-9.pdf (accessed 27 May 2020).

5. Chang Chen, et.al (2020) «Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial». Available at: https://www.medrxiv.org/content/ 10.1101/2020.03.17.20037432v2) (accessed 13 May 2020).

6. Leon Caly et all. (2020) «The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro» Available at: https://doi.org/10.1016/ j.antiviral.2020.104787 (accessed 26 June 2020).

7. Amit N. Patel MD MS, et all. (2020) «Usefulness of Ivermectin in COVID-19 Illness» Available at: https://www.isglobal.org/ documents/10179/6022921/Patel+et+al.+2020+version+1.pdf/fab19388-dc3e-4593-a075-db96f4536e9d (accessed 26 June 2020).

8. Caly L, Druce JD, Catton MG, et all. (2020) The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Available at: https:// www.sciencedirect.com/science/article/pii/S0166354220302011(accessed 26 June 2020).

9. Lehrer S, Rheinstein PH. (2020) Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. In Vivo, no 34, pp.3023-6.

10. Yang SN, Atkinson SC, Wang C, et al. (2020) The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res, no 177, pp.104760.

11. Zhang X, Song Y, Ci X, et all. (2008) Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res, no 57, pp. 524–9.

12. Rajter JC, Sherman MS, Fatteh N, et all. (2020) ICON (Ivermectin in COvid Ninteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19. Available at: https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2 (accessed 10 June 2020).

13. Gorial FI, Mashhadani S, Sayaly HM, et al. (2020) Effectiveness of Ivermectin as add-on therapy in COVID-19 management (Pilot Trial). Available at: https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1 (accessed 10 June 2020).

14. Khan MS, Khan MS, Debnath Cr, et al. (2020) Ivermectin treatment may improve the prognosis of patients with COVID-19. Archivos de Bronconeumologia. Available at: https://www.archbronconeumol.org/es-ivermectin-treatment-may-improve-prognosis-articulo- S030028962030288X (accessed 10 June 2020).

15. DiNicolantonio JJ, Barroso-Arranda J, McCarty M. (2020) Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart, no 7, pp. 001350.

16. Sharun K, Dhama K, Patel SK, et al. (2020) Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob, no 19, p. 23.

17. Carvallo H, Hirsch R, Farinella ME. (2020) Safety and efficacy of the combined use of Ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv. Available at: https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1 (accessed 10 June 2020).

18. Cortegiani A, Ippolito M, Ingoglia G et al. (2020) Chloroquine for COVID-19: rationale, facts, and hopes. Crit Care, no 24, p. 210.

19. Velthuis AJ, van den Worm SH. (2010) Zn2+ inhibits Coronavirus and Arterivirus RNA polymerase activity In Vitro and Zinc ionophores block the replication of these viruses in cell culture. PLos Pathog, no 6, p. e1001176.

20. Hemila H. (2017) Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage.J Royal Soc Med Open, no 8, pp. 1–7.

21. Singh M, Das RR. (2013) Zinc for the common cold. Cochrane Database of Syst Rev. Available at: https://pubmed.ncbi.nlm.nih.gov/23775705/ (accessed 10 June 2020).

22. Hoeger J, Simon TP, Beeker T et al. (2017) Persistent low serum zinc is associated with recurrent sepsis in critically ill patients – A pilot study. PloS ONE, no 12, p.e0176069.

23. Hongchao Pan, Richard Peto, Quarraisha Abdool Karim, et al. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results.medRxiv. Available at: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1 (accessed 10 June 2020).

24. Ray WA, Murray KT, Hall K, et al. (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med, no. 366 (20), pp. 1881–90.

25. Simpson TF, Kovacs RJ, Stecker EC. (2020) Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology; Cardiology Magazine. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. 2020 Mar 29 (accessed 1 April 2020).

26. Roden D.M., Harrington R.A., Poppas A, et al. (2020) Drug Interactions on QTc in Exploratory COVID-19 Treatment. Available at: https://www. ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047521 (accessed 15 April 2020).

27. Detailed recommendations for interactions with experimental COVID-19 antiviral therapies. Circulation. Available at: https://www.covid19- druginteractions.org/prescribing-resources (accessed 15 April 2020).

28. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Available at: www.acc.org/latest-in-cardiology/ articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 (accessed 15 April 2020).

29. EVMS CRITICAL CARE COVID-19 MANAGEMENT PROTOCOL. Developed and updated by Paul Marik, M D. Chief of Pulmonary and Critical Care Medicine Eastern Virginia Medical School, Norfolk, VA. November 2nd, 2020. Available at: https://www.evms.edu/media/evms_public/ departments/internal_medicine/EVMS_Critical_Care_COVID-19_Protocol.pdf (accessed 5 November 2020).

30. A.A. Kubanov, D.G. Deryabin State Research Centre of Dermatovenerology and Cosmetology, Moscow, Russian Federation A New Look at the COVID-19 Pathogenesis: the Disease is a Generalized Viral Vasculitis, and the Lung Tissue Damage is a Variant of Angiogenic Pulmonary Edema. DOI: http://dx.doi.org/10.15690/vramn1

31. Liu B. Ya Gao, Yuejun Zhang, et al. (2020) The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis. Journal of autoimmunity, no 81(3), pp. e93–e95.

32. Renu K, Prasanna PL, Valsala Gopalakrishnan A. (2020) Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review. Life Sci., no 255, p. 117839.

33. Moore J.B., June C.H. (2020). Cytokine release syndrome in severe COVID-19. Science, no 368(6490), pp. 473–474

34. Ivan Rosas, Norbert Bräu, Michael Waters, et al. (2020) Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia. Available at: https://www. medrxiv.org/content/10.1101/2020.08.27.20183442v2 (accessed 5 November 2020).

35. Hermine O, Mariette X, Tharaux PL, et al. (2020) Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia.A randomized Clinical Trial. JAMA Intern Med. Available at: https://jamanetwork.com/journals/jamainternalmedicine/ fullarticle/2772187 (accessed 5 November 2020).

36. Stone JH, Frigault MJ, Sterling-Boyd NJ, et al. (2020) Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med, Available at: https://pubmed.ncbi.nlm.nih.gov/33085857 (accessed 5 November 2020).

37. Salvarani C, Dolci G, Massari M, et al. (2020) Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia. A randomized clinical trial. JAMA Intern Med, Available at: https://jamanetwork.com/journals/jamainternalmedicine/ fullarticle/2772186 (accessed 5 November 2020).

38. Bassetti M, Kollef MH, Timsit JF. (2020) Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Med, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479998/ (accessed 5 November 2020).

39. Siemieniuk RA, Bortoszko JJ, Ge L, et al. (2020) Drug treatments for Covid-19: living systematic review and network meta-analysis. BMJ, Available at: https://pubmed.ncbi.nlm.nih.gov/32732190/ (accessed 5 November 2020).

40. Peter Horby et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. Available at: https://www.medrxiv.org/ content/10.1101/2020.06.22.20137273v1.full.pdf/ (accessed 5 November 2020).

41. Kortikosteroidy pri COVID-19: Variativnye rekomendacii, 2 sentyabrya 2020 g. [Corticosteroids for COVID-19: Alternative Recommendations, September 2, 2020] Available at: https://www.euro.who.int/ru/health-topics/health-emergencies/coronavirus-covid-19/publications-and- technical-guidance/2020/corticosteroids-for-covid-19-living-guidance,-2-september-2020 (accessed 25 September 2020).

42. «Profilaktika, diagnostika, lechenie koronavirusnoj infekcii». Vremennye rekomendacii. Rossiya. Versiya 9 (26.10.2020). ["Prevention, diagnosis, treatment of coronavirus infection." Interim recommendations. Russia. Version 9 (10/26/2020).] Available at: https://static-0.minzdrav.gov.ru/ system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062 (accessed 30 October 2020).

43. Prikaz Ministerstva zdravoohraneniya Respubliki Belarus’ ot 24 aprelya 2020 g. № 488 «Ob otdel’nyh voprosah okazaniya medicinskoj pomoshchi pacientam s infekciej COVID-19» [Order of the Ministry of Health of the Republic of Belarus of April 24, 2020 No. 488 "On certain issues of providing medical care to patients with COVID-19 infection"]. Available at: http://www.infectology.bsmu.by/Files/2019CoV/Normat_Docs/ prikaz_mz_rb_488_ot_24.04.2020.pdf (accessed 30 May 2020).

44. Prikaz Ministerstva zdravoohraneniya Respubliki Belarus’ ot 21.10.2020 № 1106 «O nekotoryh voprosah okazaniya medicinskoj pomoshchi pacientov s infekciej COVID-19» [Order of the Ministry of Health of the Republic of Belarus dated October 21, 2020 No. 1106 "On some issues of providing medical care to patients with COVID-19 infection"] Available at: http://minzdrav.gov.by/ru/dlya-spetsialistov/normativno-pravovaya- baza/baza-npa.php?ELEMENT_ID=330258 (accessed 30 October 2020).

45. Prikaz Ministerstva zdravoohraneniya Respubliki Belarus’ ot 30.09.2020 № 1019 «O nekotoryh voprosah lecheniya pacientov v vozraste do 18 let s infekciej COVID-19» [Order of the Ministry of Health of the Republic of Belarus dated September 30, 2020 No. 1019 "On some issues of treatment of patients under the age of 18 with COVID-19 infection"] Available at: http://minzdrav.gov.by/ru/dlya-spetsialistov/normativno- pravovaya-baza/baza-npa.php?ELEMENT_ID=330250 (accessed 10 October 2020).

46. Prikaz Ministerstva zdravoohraneniya Respubliki Belarus’ot 01.07.2020 № 690 «O voprosah lecheniya pacientov s infekciej COVID-19» [Order of the Ministry of Health of the Republic of Belarus dated 01.07.2020 No. 690 "On the issues of treating patients with COVID-19 infection"] Available at: http://minzdrav.gov.by/ru/dlya-spetsialistov/normativno-pravovaya-baza/baza-npa.php?ELEMENT_ID=329975 (accessed 25 September 2020).

47. Prikaz Ministerstva zdravoohraneniya Respubliki Belarus’ ot 05.06.2020 № 615 «Ob okazanii medicinskoj pomoshchi pacientam s infekciej COVID-19» [Order of the Ministry of Health of the Republic of Belarus dated 05.06.2020 No. 615 "On the provision of medical care to patients with COVID-19 infection"] Available at: http://minzdrav.gov.by/ru/dlya-spetsialistov/normativno-pravovaya-baza/baza-npa.php?ELEMENT_ ID=329874 (accessed 25 September 2020).


Для цитирования:


Гавриленко Л.Н., Кожанова И.Н., Романова И.С., Садовская О.Г. Острые вопросы фармакотерапии коронавирусной инфекции.Позиция клинических фармакологов. Рецепт. 2020;(5):654-679. https://doi.org/10.34883/PI.2020.23.5.003

For citation:


Gavrilenko .L., Kozhanova .I., Romanova .I., Sadovskaya .O. Acute Issues of Pharmacotherapy of Coronavirus Infection. Position of a Clinical Pharmacologists. Recipe. 2020;(5):654-679. (In Russ.) https://doi.org/10.34883/PI.2020.23.5.003

Просмотров: 16


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)